Acquisition Opportunity Lantheus acquired Evergreen Theragnostics in 2025 for 250M, signaling a strong strategic expansion in radiopharmaceuticals. This creates an opportunity to engage with the parent company on potential additional CDMO services, filling gaps in scale, manufacturing capacity, and regulatory affairs support for rapid clinical development and commercialization.

Clinical Pipeline Evergreen is actively developing radioligand therapies including small cell lung cancer and has licensing agreements with Medical University of Innsbruck. Targeted outreach to their science and BD teams could unlock opportunities for process development, GMP manufacturing, and batch-scale supply agreements as programs advance.

CDMO Capabilities As a radiopharmaceutical CDMO with expertise in manufacturing process development and regulatory affairs, Evergreen represents a potential partner for fill–finish, quality systems optimization, and regulatory strategy support to accelerate time-to-market for radiopharmaceutical products.

Strategic Partnerships Past and current collaborations with Jubilant Radiopharma and institutional investors indicate a growth-friendly ecosystem. This suggests openings for co-development, licensing, or strategic alliances around new radiopharmaceuticals, kit production, or distribution arrangements in the US market.

Financial Leverage With current revenue in the low tens of millions and a total funding around sixty million, there is room to discuss scalable manufacturing capacity, longer-term supply agreements, and risk-sharing models to support expanding clinical trials and future product commercialization with Evergreen and its acquirer.